Funds holding LB Pharmaceuticals Inc
ISIN US50180M1080 · United States
- Fund holders
- 108
- Of which ETFs
- 17 91 other funds
- Value held
- 128.5M $
- Share of capital
- 15.8 % of 32.3M shares on Aug 5, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| PROFUND VP SMALL CAP ProFunds | 49 | 1.2K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 49 | 1.2K $ | 0.00 % | as of Mar 31, 2026 ↗ | |
| Russell 2000 Fund Rydex Series Funds | 44 | 1.1K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 35 | 1.1K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 26 | 641.2 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 20 | 480.2 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 6 | 144.1 $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 5 | 123.3 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| JPMorgan Small Cap Growth Fund JPMorgan Trust II | 0.83 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 0.71 % | as of Mar 31, 2026 ↗ |
| PROFUND VP PHARMACEUTICALS ProFunds | 0.69 % | as of Mar 31, 2026 ↗ |
| Calamos Timpani Small Cap Growth Fund CALAMOS INVESTMENT TRUST/IL | 0.67 % | as of Apr 30, 2026 ↗ |
| Direxion Daily Pharmaceutical & Medical Bull 3X Shares Direxion Shares ETF Trust | 0.64 % | as of Apr 30, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 0.63 % | as of Apr 30, 2026 ↗ |
| PHARMACEUTICALS ULTRASECTOR PROFUND ProFunds | 0.63 % | as of Apr 30, 2026 ↗ |
| Janus Henderson Small Cap Growth Alpha ETF Janus Detroit Street Trust | 0.62 % | as of Apr 30, 2026 ↗ |
| JPMorgan Small Cap Blend Fund JPMorgan Trust I | 0.41 % | as of Mar 31, 2026 ↗ |
| PGIM Jennison Health Sciences Fund Prudential Sector Funds, Inc. | 0.38 % | as of Feb 27, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 108 | +38 | 5,091,072 | +14.9 % |
| 2026Q1 | 70 | +60 | 4,432,627 | +329.3 % |
| 2025Q4 | 10 | 1,032,441 |
Institutional managers
73 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Deep Track Capital, LP | 3,352,804 | 82.7M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 2,470,845 | 60.9M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 2,208,604 | 54.5M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 1,839,489 | 45.3M $ | as of Mar 31, 2026 |
| Commodore Capital LP | 1,500,000 | 37M $ | as of Mar 31, 2026 |
| Caligan Partners LP | 1,438,070 | 34.6M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 1,427,568 | 33.2M $ | as of Mar 31, 2026 |
| Spruce Street Capital LP | 1,376,159 | 33.6M $ | as of Mar 31, 2026 |
| Trails Edge Capital Partners, LP | 1,319,362 | 32.5M $ | as of Mar 31, 2026 |
| Nantahala Capital Management, LLC | 1,052,894 | 26M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 923,694 | 22.8M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 915,000 | 22.6M $ | as of Mar 31, 2026 |
| Alyeska Investment Group, L.P. | 863,947 | 21.3M $ | as of Mar 31, 2026 |
| Vivo Capital, LLC | 800,000 | 19.7M $ | as of Mar 31, 2026 |
| Nan Fung Group Holdings Ltd | 630,657 | 15.6M $ | as of Mar 31, 2026 |
| JENNISON ASSOCIATES LLC | 538,216 | 13.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 518,228 | 12.8M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 504,373 | 12.4M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 416,906 | 10.3M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 363,799 | 9M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 300,000 | 7.4M $ | as of Mar 31, 2026 |
| FMR LLC | 222,508 | 5.5M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 200,000 | 4.9M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 186,095 | 4.6M $ | as of Mar 31, 2026 |
| HighVista Strategies LLC | 173,595 | 4.3M $ | as of Mar 31, 2026 |
Declared shareholders of LB Pharmaceuticals Inc
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Commodore Capital LP and 3 others | 6.80 % | 1,972,369 | as of Mar 31, 2026 · SCHEDULE 13G |
| TCG Crossover GP II, LLC and 2 others | 6.40 % | 1,839,489 | as of Mar 31, 2026 · SCHEDULE 13G |
| Caligan Partners LP and 1 other | 5.00 % | 1,438,070 | as of Mar 31, 2026 · SCHEDULE 13G |
| JPMORGAN CHASE & CO | 4.90 % | 1,427,568 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding LB Pharmaceuticals Inc". https://titelia.com/en/stocks/lb-pharmaceuticals-inc-US50180M1080